Haosen Fintech (3848) Highlights Supplemental Details on 2023 Share Schemes

Bulletin Express
2025/10/24

Haosen Fintech Group Limited (the “Company”) published additional information regarding its 2023 Share Option Scheme and 2023 Share Award Scheme in connection with the 2024 Annual Report, covering the year ended 31 December 2024. The following points reflect the key details:

No cancellation of options or awards occurred under the respective schemes during the period, with no awards granted at all under the 2023 Share Award Scheme. The number of options and awards available for grant under the defined Scheme Mandate Limit stood at 15,658,300 shares on 1 January 2024, reducing to 2,158,300 shares on 31 December 2024. Meanwhile, the Service Provider Sublimit remained at 1,565,830 shares throughout the period.

According to the Company, the total number of shares available for issue under both the 2023 Share Option Scheme and the 2023 Share Award Scheme amounted to 15,658,300 shares, representing approximately 10% of shares in issue (excluding treasury shares) as of late March 2025. The vesting period for grants under both schemes is set at 12 months from the date of grant. The maximum entitlement for each participant within 12 months is capped at 1% of the total number of issued shares (excluding treasury shares), subject to specific shareholder approvals if certain thresholds are exceeded.

The Remuneration Committee approved option grants to employees with four to ten years of service, excluding Directors and senior managers, noting that the awards aim to acknowledge past contributions while maintaining alignment with the long-term interests of the Company and its shareholders. No performance targets were included, but a 12-month vesting period was imposed. No awards were granted under the 2023 Share Award Scheme during the financial year.

The supplemental information does not affect other content in the 2024 Annual Report, and the Company has confirmed that all details remain otherwise unchanged.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10